Celldex Therapeutics Inc

NASDAQ:CLDXUnited States

Apr 17, 2024

Show headlines and story abstract

• Sector Update: Health Care Stocks Mixed Wednesday Afternoon, from 1:46PM ET on Wednesday Apr 17, 2024 by MT Newswires

  1:46PM ET on Wednesday Apr 17, 2024 by MT Newswires
  Companies Mentioned: CLDX, VNDA, NRBO
  01:46 PM EDT, 04/17/2024 (MT Newswires) -- Health care stocks were mixed in Wednesday afternoon trading, with the NYSE Health Care Index fractionally higher and the Health Care Select Sector SPDR Fund (XLV) slightly lower. The iShares Biotechnology ...

• Celldex Therapeutics Says Patient Enrollment Completed in Chronic Inducible Urticaria Treatment Study; Shares Rise, from 11:23AM ET on Wednesday Apr 17, 2024 by MT Newswires

  11:23AM ET on Wednesday Apr 17, 2024 by MT Newswires
  Companies Mentioned: CLDX
  11:23 AM EDT, 04/17/2024 (MT Newswires) -- Celldex Therapeutics (CLDX) said Wednesday that enrollment of patients has been completed in its phase 2 clinical study of barzolvolimab for the treatment of cold urticaria and symptomatic dermographism, th...

• DJ Celldex Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co., from 10:46AM ET on Wednesday Apr 17, 2024 by Dow Jones

  10:46AM ET on Wednesday Apr 17, 2024 by Dow Jones
  Companies Mentioned: CLDX
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/CLDX/analyst-ratings
  
  (END) Dow Jones Newswires
  
  April 17, 2024 10:46 ET (14:46 GMT)
  

• Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria, from 8:01AM ET on Wednesday Apr 17, 2024 by GlobeNewswire

  8:01AM ET on Wednesday Apr 17, 2024 by GlobeNewswire
  Companies Mentioned: CLDX

• Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria, from 8:01AM ET on Wednesday Apr 17, 2024 by Dow Jones

  8:01AM ET on Wednesday Apr 17, 2024 by Dow Jones
  Companies Mentioned: CLDX
  
  Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
  
  HAMPTON, N.J., April 17, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that patient enrollment has been completed in the Company's Phase 2 clinical study of barzolvolimab for the treatment of the two most common forms of chronic inducible urticaria (CIndU)--cold urticaria (ColdU) and symptomatic dermographism (SD). CIndU is characterized by the occurrence of hives or wheals that have an attributable trigger associated with them--temperatures below skin temperature in ColdU and scratching/rubbing of the skin in SD. Mast cell activation is known to be a critical driver in ColdU and SD. Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity, which is required for mast cell function and survival. In February 2024, the Company presented positive 12 week primary endpoint results from its ongoing Phase 2 study of barzolvolimab in the most common form of chronic urticaria--chronic spontaneous urticaria (CSU).